---
input_text: 'WTX101 - an investigational drug for the treatment of Wilson disease.
  INTRODUCTION: Wilson disease (WD) is a genetic disorder in which excess toxic copper
  accumulates in the liver, brain, and other tissues leading to severe and life-threatening
  symptoms. Copper overload can be assessed as non-ceruloplasmin-bound copper non-ceruloplasmin-bound
  copper (NCC) in blood. Current therapies are limited by efficacy, safety concerns,
  and multiple-daily dosing. Areas covered: This article reviews the literature on
  WTX101 (bis-choline tetrathiomolybdate), an oral first-in-class copper-protein-binding
  agent in development for the treatment of WD. Expert opinion: In a proof-of-concept
  phase II trial, once-daily WTX101 over 24 weeks rapidly lowered NCC levels and this
  was accompanied by improved neurological status without apparent initial drug-induced
  paradoxical worsening, reduced disability, stable liver function, with a favorable
  safety profile. WTX101 directly removes excess copper from intracellular hepatic
  copper stores and also forms an inert tripartite complex with copper and albumin
  in the circulation and promotes biliary copper excretion. These mechanisms may explain
  the rapid biochemical and clinical improvements observed. A phase III trial of WTX101
  is ongoing and results are eagerly awaited to confirm if WTX101 can improve the
  treatment of this devastating disease.'
raw_completion_output: |-
  primary_disease: Wilson disease

  medical_actions: oral administration of WTX101; lowered NCC levels; improved neurological status; reduced disability; stable liver function; promotes biliary copper excretion

  symptoms: excess toxic copper accumulates in the liver, brain, and other tissues; severe and life-threatening symptoms

  chemicals: bis-choline tetrathiomolybdate; copper

  action_annotation_relationships: oral administration of WTX101 (with bis-choline tetrathiomolybdate) TREATS excess toxic copper accumulates in the liver, brain, and other tissues IN Wilson disease; lowered NCC levels (with bis-choline tetrathiomolybdate) TREATS excess toxic copper IN Wilson disease; improved neurological status (with bis-choline tetrathiomolybdate) TREATS severe and life-threatening symptoms IN Wilson disease; reduced disability (with bis-choline tetrathiomolybdate) TREATS severe and life-threatening symptoms IN Wilson disease; stable liver function (with bis-choline tetrathiomolybdate) TREATS excess toxic copper accumulates in the liver IN Wilson disease; promotes biliary copper excretion (with bis-choline tetrathiomolybdate) PREVENTS excess toxic copper accumulates in the liver, brain, and other tissues IN Wilson disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  promotes biliary copper excretion (with bis-choline tetrathiomolybdate) PREVENTS excess toxic copper accumulates in the liver, brain, and other tissues IN Wilson disease

  ===

extracted_object:
  primary_disease: MONDO:0010200
  medical_actions:
    - oral administration of WTX101
    - lowered NCC levels
    - improved neurological status
    - reduced disability
    - stable liver function
    - promotes biliary copper excretion
  symptoms:
    - excess toxic copper accumulates in the liver, brain, and other tissues
    - severe and life-threatening symptoms
  chemicals:
    - bis-choline tetrathiomolybdate
    - CHEBI:28694
  action_annotation_relationships:
    - subject: oral administration of WTX101
      predicate: TREATS
      object: excess toxic copper accumulates in the liver, brain, and other tissues
      qualifier: MONDO:0010200
      subject_extension: bis-choline tetrathiomolybdate
    - subject: lowered NCC levels
      predicate: TREATS
      object: excess
      qualifier: MONDO:0010200
      subject_qualifier: with bis-choline tetrathiomolybdate
      object_qualifier: excess
      subject_extension: bis-choline tetrathiomolybdate
      object_extension: toxic copper
    - subject: improved neurological status
      predicate: TREATS
      object: severe and life-threatening symptoms
      qualifier: MONDO:0010200
      subject_qualifier: with bis-choline tetrathiomolybdate
      object_qualifier: severe
      subject_extension: bis-choline tetrathiomolybdate
    - subject: reduced disability
      predicate: TREATS
      object: symptoms
      qualifier: MONDO:0010200
      subject_qualifier: with bis-choline tetrathiomolybdate
      object_qualifier: severe and life-threatening
      subject_extension: bis-choline tetrathiomolybdate
      object_extension: severe and life-threatening
    - subject: stable liver function
      predicate: TREATS
      object: excess toxic copper accumulates in the liver
      qualifier: MONDO:0010200
      subject_qualifier: with bis-choline tetrathiomolybdate
      subject_extension: bis-choline tetrathiomolybdate
    - subject: promotes biliary copper excretion
      predicate: PREVENTS
      object: excess toxic copper accumulates in the liver, brain, and other tissues
      qualifier: MONDO:0010200
      subject_qualifier: with bis-choline tetrathiomolybdate
      subject_extension: bis-choline tetrathiomolybdate
named_entities:
  - id: MONDO:0010200
    label: Wilson's disease
  - id: MAXO:0001175
    label: liver transplantation
  - id: HP:0001695
    label: cardiac arrest
  - id: HP:0001685
    label: myocardial fibrosis
  - id: HP:0001663
    label: ventricular fibrillation
  - id: CHEBI:30703
    label: tetrathiomolybdate (TTM)
  - id: CHEBI:35176
    label: Zinc sulphate
  - id: CHEBI:35475
    label: NSAIDs
  - id: MAXO:0001001
    label: Gene therapy
  - id: HP:0006554
    label: acute liver failure
  - id: HP:0003256
    label: coagulopathy
  - id: HP:0002480
    label: hepatic encephalopathy
  - id: HP:0001337
    label: Tremor
  - id: HP:0001332
    label: Dystonia
  - id: CHEBI:28694
    label: Copper
  - id: HP:0001395
    label: Liver fibrosis
  - id: HP:0001394
    label: Cirrhosis
  - id: CHEBI:39501
    label: trientine
  - id: CHEBI:27363
    label: zinc
  - id: HP:0001410
    label: hepatic dysfunction
  - id: CHEBI:7959
    label: D-penicillamine
  - id: MAXO:0000376
    label: Liver biopsy
  - id: HP:0001404
    label: Hepatocellular necrosis
  - id: CHEBI:61049
    label: Tacrolimus
  - id: CHEBI:50868
    label: Penicillamine
  - id: HP:0001744
    label: splenomegaly
  - id: HP:0001541
    label: ascites
  - id: HP:0001260
    label: Dysarthria
  - id: HP:0001347
    label: Hyperreflexia
  - id: HP:0031843
    label: Bradyphrenia
  - id: HP:0002362
    label: Shuffling gait
  - id: HP:0002300
    label: Mutism
  - id: HP:0001621
    label: Hypophonia
  - id: CHEBI:37153
    label: Calcineurin inhibitors
  - id: CHEBI:8356
    label: Pramipexole
  - id: CHEBI:2618
    label: Amantadine
  - id: HP:0001399
    label: liver failure
  - id: HP:0000952
    label: jaundice
  - id: HP:0001919
    label: acute kidney injury
  - id: HP:0200032
    label: Kayser-Fleischer rings
  - id: MONDO:0013792
    label: Intracerebral Hemorrhage
  - id: HP:0001342
    label: Intracerebral Hemorrhage
  - id: MAXO:0000533
    label: Molecular genetic testing
  - id: HP:0001873
    label: thrombocytopenia
  - id: HP:0002344
    label: worsening neurological symptoms
  - id: HP:0001272
    label: Cerebellar Atrophy
  - id: HP:0012896
    label: abnormal motor evoked potentials (MEPs)
  - id: HP:0001392
    label: liver disease
  - id: HP:0001396
    label: cholestasis
  - id: HP:0001403
    label: macrovesicular steatosis
  - id: CHEBI:8830
    label: rhodanine
  - id: CHEBI:90299
    label: orcein
  - id: MONDO:0018874
    label: Acute Myeloid Leukemia (t-AML or AML-MRC)
  - id: CHEBI:41977
    label: Daunorubicin
  - id: CHEBI:28680
    label: Cytarabine
  - id: CHEBI:37404
    label: Elemental copper
  - id: CHEBI:16856
    label: Plasma glutathione (GSH)
  - id: CHEBI:53498
    label: Total antioxidant capacity (TAC)
  - id: CHEBI:566274
    label: Malondialdehyde (MDA)
  - id: CHEBI:33697
    label: RNAs
  - id: HP:0000989
    label: itchy skin
  - id: CHEBI:63623
    label: Dimercaptosuccinic acid
  - id: CHEBI:145810
    label: insulin
  - id: HP:0001250
    label: Epileptic seizures
  - id: HP:0001298
    label: Encephalopathy
  - id: HP:0002315
    label: Headache
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0002878
    label: Acute respiratory failure
  - id: CHEBI:166831
    label: copper chelating agents
  - id: MONDO:0004789
    label: Cholangitis
  - id: MAXO:0010026
    label: zinc supplementation
  - id: CHEBI:16796
    label: Melatonin
  - id: MAXO:0009095
    label: Zinc (Zn) therapy
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:38161
    label: Chelator
  - id: MONDO:0019542
    label: Acute Liver Failure (ALF)
  - id: HP:0002204
    label: Pulmonary embolism
  - id: HP:0100806
    label: Sepsis
  - id: HP:0001944
    label: dehydration
  - id: CHEBI:18248
    label: iron
  - id: CHEBI:18291
    label: manganese
  - id: CHEBI:22984
    label: calcium
  - id: HP:0001081
    label: Cholelithiasis
  - id: HP:0002716
    label: Lymphadenopathy
  - id: MONDO:0100193
    label: End-stage liver diseases
  - id: HP:0002040
    label: Esophageal varices
  - id: HP:0100626
    label: End-stage liver diseases
  - id: MONDO:0017014
    label: children
  - id: MAXO:0009016
    label: Botulinum toxin type A (BoNT-A) injection
  - id: CHEBI:3160
    label: Botulinum toxin type A (BoNT-A)
  - id: HP:0003088
    label: Premature osteoarthritis
  - id: HP:0002885
    label: Mallory-Denk body (MDB) formation
  - id: CHEBI:35341
    label: Steroids
  - id: CHEBI:16990
    label: Bilirubin
  - id: MONDO:0100192
    label: Liver failure
  - id: HP:0001409
    label: Portal hypertension
  - id: HP:0001402
    label: Hepatocellular carcinoma
  - id: CHEBI:30663
    label: Serum ceruloplasmin (CP)
  - id: HP:0001513
    label: obesity
  - id: CHEBI:16610
    label: spermidine
  - id: CHEBI:27881
    label: resveratrol
  - id: CHEBI:15351
    label: AcCoA
  - id: HP:0001300
    label: Parkinsonism
  - id: CHEBI:62984
    label: zinc acetate
  - id: MAXO:0000165
    label: treatment with diuretics
  - id: CHEBI:35498
    label: diuretics
  - id: CHEBI:33281
    label: antibiotics
  - id: CHEBI:50503
    label: laxatives
  - id: CHEBI:76649
    label: Aspartate aminotransferase (AST)
  - id: CHEBI:37708
    label: Alanine aminotransferase (ALT)
  - id: HP:0011967
    label: Copper deficiency
  - id: CHEBI:38127
    label: Thiocarbamate
  - id: CHEBI:25548
    label: Nitrilotriacetate
  - id: CHEBI:16494
    label: Lipoic acid
  - id: MONDO:0010651
    label: Menkes disease
  - id: MAXO:0000127
    label: genetic testing
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:18132
    label: CHOP
  - id: HP:0002665
    label: lymphoma
